[1]
Sano H, Nambu A. The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. Neurochemistry international. 2019 Mar:124():171-180. doi: 10.1016/j.neuint.2019.01.011. Epub 2019 Jan 11
[PubMed PMID: 30639196]
[2]
Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29:8(1):. doi: 10.3390/cells8010014. Epub 2018 Dec 29
[PubMed PMID: 30597973]
[3]
Galgani A, Palleria C, Iannone LF, De Sarro G, Giorgi FS, Maschio M, Russo E. Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs. Frontiers in neurology. 2018:9():1067. doi: 10.3389/fneur.2018.01067. Epub 2018 Dec 7
[PubMed PMID: 30581412]
[4]
Hara N, Nezu T, Kobatake K, Morino H, Kawakami H, Maruyama H. Treatment of intractable resting tremor of spinocerebellar ataxia 42 with zonisamide. Journal of the neurological sciences. 2019 Jan 15:396():119-120. doi: 10.1016/j.jns.2018.11.013. Epub 2018 Nov 10
[PubMed PMID: 30448718]
[5]
Brigo F, Lattanzi S, Igwe SC, Behzadifar M, Bragazzi NL. Zonisamide add-on therapy for focal epilepsy. The Cochrane database of systematic reviews. 2018 Oct 18:10(10):CD001416. doi: 10.1002/14651858.CD001416.pub4. Epub 2018 Oct 18
[PubMed PMID: 30335200]
Level 1 (high-level) evidence
[6]
Park KM, Lee BI, Shin KJ, Ha SY, Park J, Kim SE, Kim SE. Efficacy, tolerability, and blood concentration of zonisamide in daily clinical practice. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2019 Mar:61():44-47. doi: 10.1016/j.jocn.2018.11.012. Epub 2018 Nov 13
[PubMed PMID: 30446366]
[7]
Verrotti A, Striano P, Iapadre G, Zagaroli L, Bonanni P, Coppola G, Elia M, Mecarelli O, Franzoni E, Liso P, Vigevano F, Curatolo P. The pharmacological management of Lennox-Gastaut syndrome and critical literature review. Seizure. 2018 Dec:63():17-25. doi: 10.1016/j.seizure.2018.10.016. Epub 2018 Oct 26
[PubMed PMID: 30391662]
[8]
Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Park EL, Stern J, Hirtz D, Nespeca M, Gidal B, Faught E, French J. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Epilepsy currents. 2018 Jul-Aug:18(4):260-268. doi: 10.5698/1535-7597.18.4.260. Epub
[PubMed PMID: 30254527]
Level 1 (high-level) evidence
[9]
Li C, Xue L, Liu Y, Yang Z, Chi S, Xie A. Zonisamide for the Treatment of Parkinson Disease: A Current Update. Frontiers in neuroscience. 2020:14():574652. doi: 10.3389/fnins.2020.574652. Epub 2020 Dec 21
[PubMed PMID: 33408605]
[10]
Liparoti G, Burchiani B, Mencaroni E, Tripodi D, Di Cara G, Verrotti A. Individualizing doses of antiepileptic drugs. Expert opinion on drug metabolism & toxicology. 2022 Mar:18(3):219-233. doi: 10.1080/17425255.2022.2075342. Epub 2022 May 23
[PubMed PMID: 35523739]
Level 3 (low-level) evidence
[11]
Abou-Khalil BW. Update on Antiseizure Medications 2022. Continuum (Minneapolis, Minn.). 2022 Apr 1:28(2):500-535. doi: 10.1212/CON.0000000000001104. Epub
[PubMed PMID: 35393968]
[12]
Janković SM. Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects. Expert opinion on drug metabolism & toxicology. 2020 Mar:16(3):169-177. doi: 10.1080/17425255.2020.1736035. Epub 2020 Mar 2
[PubMed PMID: 32116059]
Level 3 (low-level) evidence
[13]
Supuran CT. An update on drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert opinion on drug metabolism & toxicology. 2020 Apr:16(4):297-307. doi: 10.1080/17425255.2020.1743679. Epub 2020 Mar 21
[PubMed PMID: 32172611]
Level 3 (low-level) evidence
[14]
Hakami T. Neuropharmacology of Antiseizure Drugs. Neuropsychopharmacology reports. 2021 Sep:41(3):336-351. doi: 10.1002/npr2.12196. Epub 2021 Jul 23
[PubMed PMID: 34296824]
[15]
Pennell PB, Karanam A, Meador KJ, Gerard E, Kalayjian L, Penovich P, Matthews A, McElrath TM, Birnbaum AK, MONEAD Study Group. Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study. JAMA neurology. 2022 Apr 1:79(4):370-379. doi: 10.1001/jamaneurol.2021.5487. Epub
[PubMed PMID: 35157004]